During the company's first-quarter earnings call, AstraZeneca PLC highlighted that a fifth new cancer drug since 2014 is on target for approval this year, and recently launched Tagrisso has become the best-selling product in its oncology portfolio. Later in the day, the UK firm also announced that Lokelma (sodium zirconium cyclosilicate, or ZS-9) had been approved by the US FDA to treat adults with hyperkalemia, a condition characterized by elevated potassium that particularly affects patients with chronic kidney disease and those on certain heart failure medicines.
AstraZeneca’s CEO Pascal Soriot made grand promises back in 2014 while fending off takeover bids for the company from US...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?